Overview
- University of Manchester researchers, working with Danish teams, report a dual‑marker blood test that identified glioblastoma with greater than 90% accuracy in a published study.
- The markers—coagulation factor IX (F9) and cartilage oligomeric matrix protein (COMP)—showed stable signals and reflected tumour response across surgery, radiotherapy and chemotherapy.
- A prospective clinical trial has launched at six UK sites and four international sites to validate diagnostic performance and real‑world monitoring utility.
- Findings were published in Neuro‑oncology Advances, with The Brain Tumour Charity helping fund the work and highlighting the potential for earlier, less invasive assessment.
- Researchers envision GP triage and a simple point‑of‑care device in the future, contingent on larger trials, regulatory review and demonstration of clinical benefit.